about
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implicationsFighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.Reverse immunoediting: When immunity is edited by antigen.Functional avidity-driven activation-induced cell death shapes CTL immunodominance.Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters.A large number of T lymphocytes recognize Moloney-murine leukemia virus-induced antigens, but a few mediate long-lasting tumor immunosurveillance.Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of ItalySurvivin expression impacts prognostically on NSCLC but not SCLC
P50
Q36004284-8CA950A8-090A-4608-BFE3-1BC64555ACFCQ36287972-DD9F660C-FE72-49A9-8820-19721555CE1AQ37667998-BCA6735A-234E-4CE6-8723-D17E9E5C0798Q38821761-B204AB58-C5EE-4C84-AD0C-BC148E215DEBQ38954082-445EFA3C-F1EB-4DD7-AEC8-C364C3762150Q40327296-6D78D903-A688-4611-B380-F1AB3AA01D09Q40432657-21287AB1-40CA-47CD-A01F-3BC3A6E7C705Q40618309-0440D4C0-C2C4-4670-AE75-3450455CC61DQ41338135-E5748C23-1008-4F3B-9161-036D80D72283Q58486119-3917CBD4-3EEE-4AC8-855D-DF05D0A66641Q61884165-A09ABEA0-44F7-4527-8540-1C63147DD1A0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvia Dalla Santa
@ast
Silvia Dalla Santa
@en
Silvia Dalla Santa
@es
Silvia Dalla Santa
@nl
type
label
Silvia Dalla Santa
@ast
Silvia Dalla Santa
@en
Silvia Dalla Santa
@es
Silvia Dalla Santa
@nl
prefLabel
Silvia Dalla Santa
@ast
Silvia Dalla Santa
@en
Silvia Dalla Santa
@es
Silvia Dalla Santa
@nl
P106
P1153
6507424698
P31
P496
0000-0002-5616-6494